Article

Patient Forum in NYC will Focus on Hairy Cell Leukemia

Author(s):

Hairy Cell Leukemia Foundation

The Hairy Cell Leukemia Foundation will host a free patient forum on July 17th with guest speaker Dr. Martin Tallman from Memorial Sloan Kettering Cancer Center. This forum is free and open to the public and will cover a range of issues related to patients’ journey with hairy cell leukemia.

The Hairy Cell Leukemia Foundation will host a free patient forum on July 17th with guest speaker Dr. Martin Tallman from Memorial Sloan Kettering Cancer Center. This forum is free and open to the public and will cover a range of issues related to patients’ journey with hairy cell leukemia. There will be ample time for audience Q&A.

Understanding Hairy Cell Leukemia

When: July 17th at 5:30 pm Eastern

Where: Webster Library, 1465 York Avenue, New York City, NY

Featuring: Dr. Martin Tallman, Memorial Sloan Kettering Cancer Center

Hosted by the Hairy Cell Leukemia Foundation

Advance registration is encouraged: https://www.hairycellleukemia.org/forums

Related Videos
Image of a woman with brown shoulder-length hair, wearing a khaki colored blazer.
Image of Dr. Jorge Cortes; a man with short dark hair wearing a suit.
Image of a man with brown hair.
Image of a woman with short brown hair and glasses.
Image of a woman with short brown hair and glasses.
Image of a man with brown hair and a suit and tie.
Image of a woman with brown bobbed hair with glasses.
Related Content
FDA approves Ryoncil for children with GVHD.
December 18th 2024

Ryoncil Receives FDA Approval for Children With GVHD

Darlene Dobkowski, MA
This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Image of blood test.
December 10th 2024

Venclexta Plus Mavenclad Boosts Response Rates in AML, MDS

Ariana Pelosci
The Venclexta-based regimen improved complete response rates in patients with acute myeloid leukemia and myelodysplastic syndromes.
Top Headlines on CAR-T Cell Therapy
December 4th 2023

Top Headlines on CAR-T Cell Therapy

Alex Biese Brielle Benyon
From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.
Illustration of blood cells.
December 8th 2024

Scemblix May Outperform Standard Treatments for Chronic Myeloid Leukemia

Megan Hollasch
Scemblix resulted in better outcomes and fewer side effects compared to standard tyrosine kinase inhibitor therapies in patients with chronic myeloid leukemia.
Image of blood test.
December 8th 2024

Tecartus Shows Similar Efficacy Across Age Groups in Leukemia

Kyle Doherty
Tecartus demonstrated similar effectiveness across age groups of patients with relapsed or refractory B-cell acute lymphoblastic leukemia.